EUROIMMUN US Revenue and Competitors
Estimated Revenue & Valuation
- EUROIMMUN US's estimated annual revenue is currently $25.4M per year.
- EUROIMMUN US's estimated revenue per employee is $251,000
Employee Data
- EUROIMMUN US has 101 Employees.
- EUROIMMUN US grew their employee count by 6% last year.
EUROIMMUN US's People
Name | Title | Email/Phone |
---|
EUROIMMUN US Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $7.8M | 31 | 11% | N/A | N/A |
#2 | $12.3M | 49 | -4% | N/A | N/A |
#3 | $15.1M | 60 | 7% | N/A | N/A |
#4 | $8.8M | 35 | -8% | N/A | N/A |
#5 | $3M | 12 | 9% | N/A | N/A |
#6 | $300.4M | 1197 | 3% | N/A | N/A |
#7 | $311.7M | 1242 | 2% | N/A | N/A |
#8 | $0.3M | 1 | -96% | N/A | N/A |
#9 | $8.3M | 33 | 3% | N/A | N/A |
#10 | $13.6M | 54 | 8% | N/A | N/A |
What Is EUROIMMUN US?
EUROIMMUN US, Inc. is a wholly owned subsidiary of PerkinElmer family, a world leader in the field of medical diagnostics. At EUROIMMUN we believe that correct diagnosis is the pre-requisite to proper treatment. To this end we manufacture, distribute and provide support for in-vitro diagnostic products of high quality in the fields of autoimmune disease, infectious disease, allergy and molecular testing. Quality, Consistency, Safety, Performance, and Value are our key elements to sustainability and commitment to meet and exceed the Customer requirements, and National and International standards. Our customers are our most important business partners. The company's global success is attributed to its dedication of delivering the highest quality products matched with unsurpassed scientific and technical support. When it comes to your diagnostics needs: EUROIMMUN means Everything!
keywords:N/AN/A
Total Funding
101
Number of Employees
$25.4M
Revenue (est)
6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $30.5M | 122 | 4% | N/A |
#2 | $163.6M | 429 | 9% | N/A |